Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...

Longtime biotech executive Jeff Behrens ventured out of the C-Suite earlier this year, opening the first life sciences-focused incubator in Newton. Now he's expanding the project amid broader demand for shared lab space.